Poziotinib - Hanmi Pharmaceutical

Drug Profile

Poziotinib - Hanmi Pharmaceutical

Alternative Names: HM-781-36B; NOV-120101

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Chonnam National University Hospital; Chungnam National University; Hanmi Pharmaceutical; Konkuk University Medical Center; Korean Association for the Study of Targeted Therapys; Kosin University Gospel Hospital; Kyungpook National University Medical School; Spectrum Pharmaceuticals; University of Texas M. D. Anderson Cancer Center; Yonsei University Health System
  • Class Anilinouracils; Antineoplastics; Piperidines; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Gastric cancer; Head and neck cancer; Lung cancer; Non-small cell lung cancer
  • Clinical Phase Unknown Colorectal cancer

Most Recent Events

  • 20 Nov 2017 Chemical structure information added
  • 18 Oct 2017 Efficacy and adverse events data from a phase II trial in Non-small-cell lung cancer released by Spectrum Pharmaceuticals
  • 13 Oct 2017 Phase-II POZITIVE20-1 clinical trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03318939)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top